Literature DB >> 22875151

Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).

Ivana Z Basta1, Tatjana D Pekmezović, Stojan Z Perić, Darija B Kisić-Tepavčević, Vidosava M Rakočević-Stojanović, Zorica D Stević, Dragana V Lavrnić.   

Abstract

The aim of this study was to assess factors that might influence the health-related quality of life (HRQoL) in patients with myasthenia gravis (MG). A cross-sectional study was performed including 230 consecutive patients with MG. Severity of the disease was estimated according to the MGFA classification and QMG score. HRQoL was assessed by the SF-36 questionnaire. Depressive and anxiety symptoms were assessed using the Hamilton rating scales for depression and anxiety, respectively. Social support was measured by the Multidimensional Scale of Perceived Social Support (MSPSS), and acceptance of the disease by the Acceptance of Illness Scale. The significant demographic predictors of worse HRQoL in MG patients were older age (p = 0.025) and lower education (p = 0.012). Among clinical features, significant independent contributing factors of worse HRQoL were more severe form of the disease according to MGFA (p = 0.001) and higher QMG score (p = 0.001). Finally, psychosocial predictors of worse quality of life were lower MSPSS score (p = 0.001), poor acceptance of the disease (p = 0.001), as well as higher levels of anxiety and depression (p = 0.001). Our study revealed that the HRQoL in patients with MG is similarly reduced in its psychological and physical aspects. These results may have a practical implication pointing out that different aspects of psychosocial support should be added to the regular therapeutic protocols.

Entities:  

Mesh:

Year:  2012        PMID: 22875151     DOI: 10.1007/s10072-012-1170-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Coping with chronic illness: a study of illness controllability and the influence of coping strategies on psychological adjustment.

Authors:  B J Felton; T A Revenson
Journal:  J Consult Clin Psychol       Date:  1984-06

Review 4.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

5.  Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992).

Authors:  D Lavrnić; M Jarebinski; V Rakocević-Stojanović; Z Stević; S Lavrnić; S Pavlović; R Trikić; I Tripković; V Nesković; S Apostolski
Journal:  Acta Neurol Scand       Date:  1999-09       Impact factor: 3.209

6.  Quality of life in patients with treated and clinically stable Wilson's disease.

Authors:  Marina Svetel; Tatjana Pekmezović; Aleksandra Tomić; Nikola Kresojević; Aleksandra Potrebić; Rada Ješić; Vladimir S Kostić
Journal:  Mov Disord       Date:  2011-05-18       Impact factor: 10.338

7.  Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes.

Authors:  Alberto Raggi; Matilde Leonardi; Renato Mantegazza; Silvia Casale; Giulia Fioravanti
Journal:  Neurol Sci       Date:  2010-04       Impact factor: 3.307

8.  Disease-specific measure of quality of life for myasthenia gravis.

Authors:  Larry L Mullins; Melissa Y Carpentier; Robert H Paul; Donald B Sanders
Journal:  Muscle Nerve       Date:  2008-08       Impact factor: 3.217

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

10.  Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  Neurol Sci       Date:  2009-10-09       Impact factor: 3.307

View more
  14 in total

1.  Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.

Authors:  Ivo Bozovic; Jelena Ilic Zivojinovic; Stojan Peric; Marko Kostic; Vukan Ivanovic; Dragana Lavrnic; Ivana Basta
Journal:  J Neurol       Date:  2021-09-04       Impact factor: 4.849

2.  Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey.

Authors:  Milada Mahic; Ali M Bozorg; Jonathan J DeCourcy; Keisha J Golden; Gregor A Gibson; Christian F Taylor; Angela Ting; Tyler J Story; Anna Scowcroft
Journal:  Neurol Ther       Date:  2022-07-20

3.  COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.

Authors:  Stojan Peric; Milos Rankovic; Ivo Bozovic; Vanja Radosavljevic; Ivan Marjanovic; Ivana Basta; Dragana Lavrnic
Journal:  Acta Neurol Belg       Date:  2022-10-24       Impact factor: 2.471

4.  Depression in myasthenia gravis: a heterogeneous and intriguing entity.

Authors:  Yury V Gavrilov; Tatjana M Alekseeva; Olga A Kreis; Philipp O Valko; Konrad P Weber; Yulia Valko
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

Review 5.  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature.

Authors:  Nathaly Garzón-Orjuela; Laura van der Werf; Laura Catalina Prieto-Pinto; Pieralessandro Lasalvia; Camilo Castañeda-Cardona; Diego Rosselli
Journal:  Intractable Rare Dis Res       Date:  2019-11

6.  Social support: an important factor for quality of life in women with hirsutism.

Authors:  Maria Palmetun Ekbäck; Magnus Lindberg; Eva Benzein; Kristofer Årestedt
Journal:  Health Qual Life Outcomes       Date:  2014-12-20       Impact factor: 3.186

7.  Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.

Authors:  Yuriko Nagane; Hiroyuki Murai; Tomihiro Imai; Daisuke Yamamoto; Emiko Tsuda; Naoya Minami; Yasushi Suzuki; Tetsuya Kanai; Akiyuki Uzawa; Naoki Kawaguchi; Masayuki Masuda; Shingo Konno; Hidekazu Suzuki; Masashi Aoki; Kimiaki Utsugisawa
Journal:  BMJ Open       Date:  2017-02-23       Impact factor: 2.692

Review 8.  Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence.

Authors:  Yanjun Liu; Xiangqi Tang
Journal:  Front Psychiatry       Date:  2018-09-25       Impact factor: 4.157

9.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Authors:  M I Boldingh; L Dekker; A H Maniaol; C Brunborg; A F Lipka; E H Niks; J J G M Verschuuren; C M E Tallaksen
Journal:  Health Qual Life Outcomes       Date:  2015-08-01       Impact factor: 3.186

10.  Determinants of quality of life in Brazilian patients with myasthenia gravis.

Authors:  Aline Mansueto Mourão; Rodrigo Santiago Gomez; Luiz Sergio Mageste Barbosa; Denise da Silva Freitas; Elizabeth Regina Comini-Frota; Arthur Kummer; Stella Maris Aguiar Lemos; Antonio Lucio Teixeira
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.